Sun Pharmaceutical Patent-Cliff Exposure & CMS Drug Spending Portfolio
Sun Pharmaceutical (Princeton, NJ): 48 reconciled FDA prescription therapies (21.9% 2025 to 2030 cliff risk), $472.8M 2024 CMS Part D & Medicaid spend, and 11 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Princeton, NJ |
| Reconciled FDA Portfolio Therapies | 48 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 21.9% |
| Primary Portfolio LOE Date | 2028-01-01 |
| 2024 CMS Total Public Spend | $472.8M |
| 2024 Medicare Part D Spend | $240.3M |
| 2024 Medicaid Spend | $232.5M |
| California HCAI SB 17 Filings | 11 WAC filings (max 21.1% 2-yr change) |